Peritoneal dialysis in diabetic patients

Advances in Renal Replacement Therapy

Volumn 8, Issue 1, 2001, Pages 22-41

  Passadakis, Ploumis ^a,b   Oreopoulos, Dimitrios ^a,b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diabetic patients; ESRD; Peritoneal dialysis

Indexed keywords

ARTICLE; CANADA; COMORBIDITY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; DISEASE COURSE; EUROPE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL; TECHNIQUE; UNITED STATES;

EID: 0035128443     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/jarr.2001.21704     Document Type: Article

References (99)

1. USRDS 1999 Annual Data Report. Annual data report. USRDS, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
2. Diabetic patients on dialysis: A changing picture
3. Continuous ambulatory peritoneal dialysis in 224 diabetics with end stage renal disease Evidence of improved survival over the past 10 years
4. Survival oI diabetic patients on peritoneal dialysis or hemodialysis
5. Peritoneal dialysis prescriptions for diabetic patients
6. Hemodialysis in diabetics
7. Hemodialysis causes severe orthostatic reduction in cerebral blood flow velocity in diabetic patients
8. Long-term outcome of diabetic patients receiving peritoneal dialysis
9. Analysis of factors in the prognosis of diabetics on continuous ambulatory peritoneal dialysis (CAPD): Long-term experience
10. Continuous ambulatory peritoneal dialysis (CAPD) in patients with diabetic nephropathy
11. CAPD in end stage patients with renal disease due to diabetes mellitus - An update
12. Prevalence of malnutrition in Mexican CAPD diabetic and nondiabetic patients
13. Diagnosis of protein calorie malnutrition in diabetic patients on hemodialysis and peritoneal dialysis
14. Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients
15. Ten years experience of CAPD in diabetics: Comparison of results with non-diabetics
16. A six-year comparison of patient and technique survivals in CAPD and HD
17. Predictors of survival in continuous ambulatory peritoneal dialysis patients: A five-year prospective study
18. Nutritional parameters in diabetic patients on CAPD
19. Adequacy of continuous peritoneal dialysis: Morbidity and mortality in chronic peritoneal dialysis
20. Comparison of 2 year survival on hemodialysis (HD) and peritoneal dialysis (PD) with dose of dialysis matched using the peak concentration hypothesis
21. Adequacy of peritoneal dialysis
22. The influence of small solute clearance on dietary protein intake in continuous ambulatory peritoneal dialysis patients: A methodologic analysis based on cross-sectional and prospective studies
23. Race and diabetes as death predictors in hemodialysis patients
24. A survey of the NIH CAPD Registry population with end-stage renal disease attributed to diabetic nephropathy
25. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years
26. Is CAPD or Haemodialysis better? CAPD is more advantageous
27. Increased peritoneal permeability to albumin in streptozotocin diabetic rats
28. An analysis of adequacy of dialysis in a selected population on CAPD for over 3 years: The influence of urea and creatinine kinetics
29. Higher membrane permeability predicts poorer patient survival
30. Death risk predictors among peritoneal dialysis and hemodialysis patients: A preliminary comparison
31. Alterations in serum lipids and apolipoproteins in male type 1 (insulin-dependent) diabetic patients with microalbuminuria
32. Serum lipids and lipoproteins in insulin-dependent diabetic patients with persistent microalbuminuria
33. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis
34. The uremic dyslipidemia: A cross-sectional and longitudinal study
35. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis
36. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients
37. Longitudinal lipid profiles on CAPD: Their relationship to weight gain, comorbidity, and dialysis factors
38. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration
39. Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients?
40. Levels of lipoprotein (a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM
41. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis
42. Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients receiving CAPD
43. Is atherosclerosis accelerated by CAPD?
44. Advanced glycation end products in continuous ambulatory peritoneal dialysis patients
45. Reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia
46. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complication
47. Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: A multicenter study
48. Comparison of survival in continuous ambulatory peritoneal dialysis and hospital haemodialysis: A multicentric study
49. Characteristics of long-term peritoneal dialysis survivors: 18 years experience in one center
50. Outcome of renal replacement treatment in patients with diabetes mellitus
51. Renal replacement treatment for diabetic patients in New-castle upon Tyne and the Northern region, 1964-88
52. Ten years' experience with continuous ambulatory peritoneal dialysis
53. Long-term outcome in continuous ambulatory peritoneal dialysis: A 10-year survey by the Italian Cooperative Peritoneal Dialysis Study Group
54. Diabetic patients on renal replacement therapy: Analysis of Catalan Registry data. Renal Registry Committee
55. Treatment of end-stage diabetic nephropathy: Over a decade of experience at one institution
56. Clinical aspects of continuous ambulatory peritoneal dialysis in diabetics
57. Dialytic therapy for diabetic patients with terminal renal failure
58. Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease: A combined experience of two North American centers
59. Comparison of long-term survival between hemodialysis and peritoneal dialysis
60. What really happens to people on long-term peritoneal dialysis?
61. Nine patients treated for more than 10 years with continuous ambulatory peritoneal dialysis
62. CAPD viability: A long-term comparison with hemodialysis
63. Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis
64. USRDS 1991 Annual Data Report, the National Institute of Diabetes and Digestive and Kidney Diseases
65. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis
66. Continuous ambulatory peritoneal dialysis and hemodialysis: Comparison of patient mortality with adjustment for comorbid conditions
67. Comparison of continuous ambulatory peritoneal dialysis and hemodialysis patient survival with evaluation of trends during the 1980s
68. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates
69. Mortality risks of peritoneal dialysis and hemodialysis
70. Trends in mortality on peritoneal dialysis: Canada, 1981-1997
71. Comparative mortality of hemodialysis and peritoneal dialysis in Canada
72. Analysis of the effects of increasing delivered dialysis treatment to malnourished peritoneal dialysis patients
73. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients
74. Recovery of renal function in patients treated by CAPD
75. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha
76. Effects of cytokines on vascular endothelium; their role in vascular and immune injury
77. Role of reactive oxygen metabolites in experimental glomerular disease
78. The influence of dialysis treatment modality on the decline of remaining renal function
79. Preservation of glomerular filtration rate on dialysis when adjusted for patient dropout
80. Rate of decline of residual renal function in patients on continuous ambulatory peritoneal dialysis and factors affecting it
81. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis
82. Predictors of survival in continuous ambulatory peritoneal dialysis patients: The importance of left ventricular hypertrophy and diabetic nephropathy
83. A selection adjusted comparison of hospitalization on continuous ambulatory peritoneal dialysis and haemodialysis
84. Patient survival, a change in methods, and hospitalization in CAPD and hemodialysis
85. Morbidity and mortality of diabetic patients on dialysis in a 10-year program: Value of combined treatment
86. Morbidity and mortality of CAPD and hemodialysis
87. Annual Data Report: Hospitalization
88. Hospitalization in peritoneal dialysis patients
89. Transplantation versus dialysis: A study of quality of life
90. Psychosocial adaptation of CAPD and centre hemodialysis patients
91. Quality of life in patients on chronic dialysis: Self-assessment. 3 months after the start of treatment
92. Quality of life over time in dialysis: The Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group
93. Assessment of handicap in chronic dialysis diabetic patients (Uremidiab section study)
94. Differences in quality of life across renal replacement therapies: A meta-analytic comparison
95. Physical activity and employment status on maintenance dialysis
96. Clinical imperatives in diabetic nephropathy: The devasting impact of comorbidity
97. The clinical evaluation of chemotherapeutic agents in cancer
98. Management choices in diabetic end-stage renal disease